| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| equivalentClass
| |
| Concept_In_Subset
| |
| Semantic_Type
| - Pharmacologic Substance
- Nucleic Acid, Nucleoside, or Nucleotide
|
| Preferred_Name
| |
| NSC_Code
| |
| UMLS_CUI
| |
| CAS_Registry
| |
| Accepted_Therapeutic_Use_For
| - Acute lymphocytic leukemia; Acute myelogenous leukemia; Crohns disease; Hodgkins lymphoma in children; Lymphoblastic lymphoma; Ulcerative colitis
|
| In_Clinical_Trial_For
| - Acute lymphoblastic leukemia; Acute promyelocytic leukemia; Anaplastic large cell lymphoma; Chronic myelogenous leukemia; Lymphoblastic lymphoma; Primary myelodysplastic syndrome
|
| FDA_UNII_Code
| |
| Contributing_Source
| |
| ALT_DEFINITION
| - A drug used to treat acute lymphatic leukemia. It belongs to the family of drugs called antimetabolites.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Chemical_Formula
| |
| Legacy_Concept_Name
| |
| CHEBI_ID
| |
| FULL_SYN
| - 6-MPSYDTPNSC0000755
- MercaleukimSYDTPNSC0000755
- MercaleukinSYDTPNSC0000755
- Purine, 6-mercapto-SYDTPNSC0000755
- MernSYDTPNSC0000755
- Puri-NetholFBNCI
- MercaleukimFBNCI
- MercaleukinSYNCI
- PurinethiolFBNCI
- Purine-6-thiol (8CI)SYDTPNSC0000755
- PurinetholPTNCI-GLOSSCDR0000413955
- 6-ThiopurineSYDTPNSC0000755
- 6 ThiopurineSYNCI
- 6-ThiopurineSYNCI
- Purine-6-thiol, monohydrateSYDTPNSC0000755
- U-4748SYDTPNSC0000755
- 6-PurinethiolSYNCI
- 6-PurinethiolSYDTPNSC0000755
- AzathiopurineSYNCI
- MERCAPTOPURINEPTFDAE7WED276I5
- 6-ThioxopurineSYNCI
- MercaptopurinePTNCI
- 6-ThioxopurineSYDTPNSC0000755
- Purine-6-thiol MonohydrateSNNCI
- MercaptopurinumBRNCI
- 6-MPABNCI
- 6H-Purine-6-thione, 1,7-dihydro- (9CI)SNNCI
- IsmipurSYDTPNSC0000755
- MernSYNCI
- Purine-6-thiol, MonohydrateSNNCI
- 6-MercaptopurineSYNCI
- 6H-Purine-6-thione, 1,7-dihydro- (9CI)SYDTPNSC0000755
- 3H-Purine-6-thiolSNNCI
- Mercapto-6-purineSNNCI
- U-4748CNNCI
- LeukerinSYDTPNSC0000755
- LeupurinSYDTPNSC0000755
- 6-Mercaptopurine MonohydrateSYNCI
- 6-MercaptopurineSYDTPNSC0000755
- WR-2785CNNCI
- mercaptopurinePTNCI-GLOSSCDR0000046639
- Bw 57-323HSYDTPNSC0038887
- NCI-C04886SYDTPNSC0000755
- 6 ThiohypoxanthineSYNCI
- 3H-Purine-6-thiolSYDTPNSC0000755
- IsmipurFBNCI
- 1,7-Dihydro-6H-purine-6-thioneSNNCI
- MercaptopurinePTDCP06674
- 7-Mercapto-1,3,4,6-tetrazaindeneSYDTPNSC0000755
- Alti-MercaptopurineFBNCI
- Purine-6-thiol (8CI)SNNCI
- FlocofilFBNCI
- LeukerinFBNCI
- LeupurinSYNCI
- MercapurinSYDTPNSC0000755
- PurimetholSYDTPNSC0000755
- PurinetholSYDTPNSC0000755
- BW 57-323HCNNCI
- 7-Mercapto-1,3,4,6-tetrazaindeneSNNCI
- 1,7-Dihydro-6H-purine-6-thione MonohydrateSNNCI
- Puri-NetholSYDTPNSC0000755
- MercaptinaFBNCI
- MercapurinSYNCI
- 6 MPSYDTPNSC0000755
- PurinetholBRNCI
- PurimetholSYNCI
|
| DEFINITION
| - A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)NCI
|
| code
| |
| is someValuesFrom
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)